Phase II study to evaluate the efficacy of the combination of trimipramine and atezolizumab with bevacizumab in patients with recurrent glioblastoma. PHENIX (SAKK 70/24)

This is a two-arm study: in the first arm (48 patients), trimipramine and atezolizumab will be added to standard of care (SoC), bevacizumab, following diagnosis of a first recurrence of glioblastoma (GBM). The aim of this cohort is to evaluate the clinical efficacy of this triple combination in the treatment of recurrent GBM. In the second arm, patients with a medical indication for surgery of the first tumor recurrence will start a combined treatment with trimipramine and atezolizumab prior to the planned surgery. Bevacizumab is then introduced simultaneously with trimipramine and atezolizumab. The aim of this cohort is to confirm the achievable trimipramine level in the tumor tissue and cerebrospinal fluid (CSF).

(BASEC)